Kailera Therapeutics, Inc. (NASDAQ:KLRA) Short Interest Update

Kailera Therapeutics, Inc. (NASDAQ:KLRA) was the target of a significant increase in short interest in the month of April. As of April 30th, there was short interest totaling 1,954,558 shares, an increase of ? from the April 15th total of 0 shares. Based on an average daily volume of 1,694,308 shares, the short-interest ratio is presently 1.2 days. Currently, 1.6% of the shares of the company are sold short.

Kailera Therapeutics Stock Down 7.1%

KLRA stock traded down $1.49 during mid-day trading on Monday, reaching $19.55. 601,971 shares of the company traded hands, compared to its average volume of 787,465. Kailera Therapeutics has a 52-week low of $19.11 and a 52-week high of $28.23.

Insider Buying and Selling at Kailera Therapeutics

In other news, Director Andrew T. Kaplan acquired 8,398,438 shares of Kailera Therapeutics stock in a transaction on Monday, April 20th. The stock was acquired at an average cost of $16.00 per share, with a total value of $134,375,008.00. Following the completion of the acquisition, the director owned 26,255,581 shares in the company, valued at approximately $420,089,296. This trade represents a 47.03% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Rtw Investments, Lp acquired 500,000 shares of Kailera Therapeutics stock in a transaction on Monday, April 20th. The shares were purchased at an average cost of $16.00 per share, with a total value of $8,000,000.00. Following the completion of the acquisition, the insider owned 10,776,820 shares of the company’s stock, valued at $172,429,120. This trade represents a 4.87% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders bought 10,460,938 shares of company stock valued at $167,375,008.

Analyst Upgrades and Downgrades

Several research firms have commented on KLRA. Evercore began coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating on the stock. Wall Street Zen raised shares of Kailera Therapeutics to a “hold” rating in a report on Saturday, April 25th. JPMorgan Chase & Co. assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set an “overweight” rating and a $30.00 target price on the stock. William Blair assumed coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating on the stock. Finally, Zacks Research raised shares of Kailera Therapeutics to a “hold” rating in a report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $42.75.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.